Regadenoson Pregnancy and Breastfeeding Warnings
Brand names: Lexiscan
Medically reviewed by Drugs.com. Last updated on Apr 1, 2024.
Regadenoson Pregnancy Warnings
Use is not recommended unless clearly needed.
US FDA pregnancy category: Not Assigned.
Risk Summary: There is no data available regarding use in pregnant women to inform a drug-associated risk.
Animal studies have revealed increased embryofetal loss and fetotoxicity at doses that produced maternal toxicity. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
Regadenoson Breastfeeding Warnings
Based on the pharmacokinetics of this drug, it should be cleared 10 hours after administration.
A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother; otherwise, the mother should pump and discard breast milk for 10 hours following administration of this drug.
Excreted into human milk: Unknown
Excreted into animal milk: Unknown
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- Cerner Multum, Inc. UK Summary of Product Characteristics.
- Product Information. Lexiscan (regadenoson). Astellas Pharma US, Inc. 2008.
References for breastfeeding information
- Cerner Multum, Inc. UK Summary of Product Characteristics.
- Product Information. Lexiscan (regadenoson). Astellas Pharma US, Inc. 2008.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
